Integra Lifesciences Holdings Corp (NASDAQ:IART) – Equities researchers at Cantor Fitzgerald increased their FY2019 earnings per share (EPS) estimates for Integra Lifesciences in a report released on Thursday, July 25th. Cantor Fitzgerald analyst C. Bijou now anticipates that the life sciences company will earn $2.73 per share for the year, up from their previous estimate of $2.70. Cantor Fitzgerald also issued estimates for Integra Lifesciences’ FY2020 earnings at $3.04 EPS.
Other equities research analysts have also recently issued reports about the company. JMP Securities boosted their price target on Facebook from $220.00 to $250.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. ValuEngine upgraded shares of United States Steel from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 24th. Wells Fargo & Co restated a “buy” rating and set a $125.00 price objective on shares of Tractor Supply in a research report on Thursday, July 25th. Zacks Investment Research upgraded shares of Hanmi Financial from a “sell” rating to a “hold” rating in a research report on Thursday, June 20th. Finally, BidaskClub downgraded shares of Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a research report on Saturday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. Integra Lifesciences currently has an average rating of “Hold” and an average target price of $61.92.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The business had revenue of $383.60 million during the quarter, compared to analysts’ expectations of $373.29 million. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 earnings per share.
Several institutional investors have recently made changes to their positions in the company. AGF Investments LLC boosted its stake in Integra Lifesciences by 54.2% during the 2nd quarter. AGF Investments LLC now owns 6,386 shares of the life sciences company’s stock valued at $357,000 after purchasing an additional 2,244 shares during the period. Dupont Capital Management Corp acquired a new position in Integra Lifesciences in the 2nd quarter valued at approximately $936,000. Meritage Portfolio Management acquired a new position in Integra Lifesciences in the 2nd quarter valued at approximately $570,000. First Trust Advisors LP raised its holdings in Integra Lifesciences by 922.1% in the 2nd quarter. First Trust Advisors LP now owns 211,299 shares of the life sciences company’s stock valued at $11,801,000 after acquiring an additional 190,626 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in Integra Lifesciences by 0.7% in the 2nd quarter. Fisher Asset Management LLC now owns 781,166 shares of the life sciences company’s stock valued at $43,628,000 after acquiring an additional 5,698 shares in the last quarter. Institutional investors and hedge funds own 82.18% of the company’s stock.
In other news, insider Lisa Evoli sold 2,380 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $63.00, for a total value of $149,940.00. Following the completion of the sale, the insider now owns 2,588 shares in the company, valued at $163,044. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Glenn Coleman sold 3,500 shares of the company’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $57.50, for a total value of $201,250.00. Following the completion of the sale, the chief operating officer now owns 35,194 shares of the company’s stock, valued at approximately $2,023,655. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,188 shares of company stock valued at $1,659,266. Insiders own 4.50% of the company’s stock.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
See Also: Marijuana Stocks
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.